Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 24
Filter
1.
Cogn Emot ; 32(4): 812-826, 2018 06.
Article in English | MEDLINE | ID: mdl-28814201

ABSTRACT

Adopting a temporally distant perspective on stressors reduces distress in adults. Here we investigate whether the extent to which individuals project themselves into the future influences distancing efficacy. We also examined modulating effects of age across adolescence and reactive aggression: factors associated with reduced future-thinking and poor emotion regulation. Participants (N = 83, aged 12-22) read scenarios and rated negative affect when adopting a distant-future perspective, near-future perspective, or when reacting naturally. Self-report data revealed significant downregulation of negative affect during the distant-future condition, with a similar though non-significant skin conductance pattern. Importantly, participants who projected further ahead showed the greatest distress reductions. While temporal distancing efficacy did not vary with age, participants reporting greater reactive aggression showed reduced distancing efficacy, and projected themselves less far into the future. Findings demonstrate the importance of temporal extent in effective temporal distancing; shedding light on a potential mechanism for poor emotional control associated with reactive aggression.


Subject(s)
Adolescent Behavior/psychology , Aggression/psychology , Emotions , Time Perception , Adolescent , Age Factors , Child , Female , Humans , Male , Self Report , Young Adult
2.
Bone Joint J ; 98-B(1): 28-32, 2016 Jan.
Article in English | MEDLINE | ID: mdl-26733512

ABSTRACT

AIMS: The purpose of this study was to compare the long-term results of primary total hip arthroplasty (THA) in young patients using either a conventional (CPE) or a highly cross-linked (HXLPE) polyethylene liner in terms of functional outcome, incidence of osteolysis, radiological wear and rate of revision. METHODS: We included all patients between the ages of 45 and 65 years who, between January 2000 and December 2001, had undergone a primary THA for osteoarthritis at our hospital using a CPE or HXLPE acetabular liner and a 28 mm cobalt-chrome femoral head. From a total of 160 patients, 158 (177 hips) were available for review (CPE 89; XLPE 88). The mean age, body mass index (BMI) and follow-up in each group were: CPE: 56.8 years (46 to 65); 30.7 kg/m(2) (19 to 58); 13.2 years (2.1 to 14.7) and HXLPE: 55.6 years (45 to 65); BMI: 30 kg/m(2) (18 to 51); 13.1 years (5.7 to 14.4). RESULTS: The mean Harris hip score (HHS) at final follow-up was 89.3 for the CPE group and 90.9 for the HXLPE group (p = 0.078). Osteolysis was present around 15 acetabular (17%) and 16 femoral (18%) components in the CPE hips compared with none (0%) in the HXLPE hips. The mean radiological linear wear of the CPE liners was 0.11 mm/year compared with 0.035 mm/year for the HXLPE liners (p = 0.006). The cumulative implant survival, with revision for polyethylene wear as the endpoint, was 86% (95% confidence interval 78 to 94) in the CPE group and 100% in the HXLPE group at 13 years (numbers at risk at 13 years - CPE: 65, XLPE: 61). DISCUSSION: This study shows that HXLPE liners are associated with significantly less osteolysis and a lower rate of revision THA than CPE liners at long-term follow-up. TAKE HOME MESSAGE: The findings of this study highlight the clinical benefits of using HXLPE liners in THA and support the routine use of the material in order to improve implant longevity and to decrease the number of patients needing revision for aseptic osteolysis.


Subject(s)
Arthroplasty, Replacement, Hip/methods , Hip Prosthesis , Polyethylene/therapeutic use , Aged , Arthroplasty, Replacement, Hip/instrumentation , Cross-Linking Reagents/therapeutic use , Female , Humans , Kaplan-Meier Estimate , Male , Middle Aged , Osteoarthritis, Hip/surgery , Osteolysis/etiology , Postoperative Complications/etiology , Prospective Studies , Prosthesis Design , Prosthesis Failure , Reoperation/statistics & numerical data
3.
Bone Joint J ; 97-B(12): 1640-4, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26637678

ABSTRACT

The purpose of this study was to compare clinical outcomes of total knee arthroplasty (TKA) after manipulation under anaesthesia (MUA) for post-operative stiffness with a matched cohort of TKA patients who did not requre MUA. In total 72 patients (mean age 59.8 years, 42 to 83) who underwent MUA following TKA were identified from our prospective database and compared with a matched cohort of patients who had undergone TKA without subsequent MUA. Patients were evaluated for range of movement (ROM) and clinical outcome scores (Western Ontario and McMaster Universities Arthritis Index, Short-Form Health Survey, and Knee Society Clinical Rating System) at a mean follow-up of 36.4 months (12 to 120). MUA took place at a mean of nine weeks (5 to 18) after TKA. In patients who required MUA, mean flexion deformity improved from 10° (0° to 25°) to 4.4° (0° to 15°) (p < 0.001), and mean range of flexion improved from 79.8° (65° to 95°) to 116° (80° to 130°) (p < 0.001). There were no statistically significant differences in ROM or functional outcome scores at three months, one year, or two years between those who required MUA and those who did not. There were no complications associated with manipulation. At most recent follow-up, patients requiring MUA achieved equivalent ROM and clinical outcome scores when compared with a matched control group. While other studies have focused on ROM after manipulation, the current study adds to current literature by supplementing this with functional outcome scores.


Subject(s)
Anesthetics/therapeutic use , Arthroplasty, Replacement, Knee/rehabilitation , Knee Joint/physiopathology , Manipulation, Orthopedic/methods , Osteoarthritis, Knee/surgery , Postoperative Care/methods , Recovery of Function , Adult , Aged , Aged, 80 and over , Female , Humans , Knee Joint/surgery , Male , Middle Aged , Prospective Studies , Range of Motion, Articular , Treatment Outcome
4.
Bone Joint J ; 97-B(5): 595-602, 2015 May.
Article in English | MEDLINE | ID: mdl-25922451

ABSTRACT

This was a randomised controlled trial studying the safety of a new short metaphyseal fixation (SMF) stem. We hypothesised that it would have similar early clinical results and micromovement to those of a standard-length tapered Synergy metaphyseal fixation stem. Using radiostereometric analysis (RSA) we compared the two stems in 43 patients. A short metaphyseal fixation stem was used in 22 patients and a Synergy stem in 21 patients. No difference was found in the clinical outcomes pre- or post-operatively between groups. RSA showed no significant differences two years post-operatively in mean micromovement between the two stems (except for varus/valgus tilt at p = 0.05) (subsidence 0.94 mm (SD 1.71) vs 0.32 mm (SD 0.45), p = 0.66; rotation 0.96° (SD 1.49) vs 1.41° (SD 2.95), p = 0.88; and total migration 1.09 mm (SD 1.74) vs 0.73 mm (SD 0.72), p = 0.51). A few stems (four SMF and three Synergy) had initial migration > 1.0 mm but stabilised by three to six months, with the exception of one SMF stem which required revision three years post-operatively. For most stems, total micromovement was very low at two years (subsidence < 0.5 mm, rotation < 1.0°, total migration < 0.5 mm), which was consistent with osseous ingrowth. The small sample makes it difficult to confirm the universal applicability of or elucidate the potential contraindications to the use of this particular new design of stem.


Subject(s)
Hip Prosthesis , Osteoarthritis, Hip/surgery , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Prospective Studies , Prosthesis Design , Prosthesis Failure , Radiostereometric Analysis
5.
Bone Joint J ; 95-B(6): 758-63, 2013 Jun.
Article in English | MEDLINE | ID: mdl-23723268

ABSTRACT

The purpose of this study was to examine the complications and outcomes of total hip replacement (THR) in super-obese patients (body mass index (BMI) > 50 kg/m(2)) compared with class I obese (BMI 30 to 34.9 kg/m(2)) and normal-weight patients (BMI 18.5 to 24.9 kg/m(2)), as defined by the World Health Organization. A total of 39 THRs were performed in 30 super-obese patients with a mean age of 53 years (31 to 72), who were followed for a mean of 4.2 years (2.0 to 11.7). This group was matched with two cohorts of normal-weight and class I obese patients, each comprising 39 THRs in 39 patients. Statistical analysis was performed to determine differences among these groups with respect to complications and satisfaction based on the Western Ontario and McMaster Universities (WOMAC) osteoarthritis index, the Harris hip score (HHS) and the Short-Form (SF)-12 questionnaire. Super-obese patients experienced significantly longer hospital stays and higher rates of major complications and readmissions than normal-weight and class I obese patients. Although super-obese patients demonstrated reduced pre-operative and post-operative satisfaction scores, there was no significant difference in improvement, or change in the score, with respect to HHS or the WOMAC osteoarthritis index. Super-obese patients obtain similar satisfaction outcomes as class I obese and normal-weight patients with respect to improvement in their scores. However, they experience a significant increase in length of hospital stay and major complication and readmission rates.


Subject(s)
Arthroplasty, Replacement, Hip/methods , Obesity, Morbid/complications , Osteoarthritis, Hip/surgery , Postoperative Complications/epidemiology , Adult , Aged , Body Mass Index , Female , Humans , Incidence , Length of Stay/trends , Male , Middle Aged , Ontario/epidemiology , Osteoarthritis, Hip/complications , Prognosis , Retrospective Studies , Risk Factors , Surveys and Questionnaires , Treatment Outcome
6.
Arch Dis Child ; 96(7): 694-6, 2011 Jul.
Article in English | MEDLINE | ID: mdl-20584848

ABSTRACT

BACKGROUND: The incidence of vitamin D deficiency is unclear in the context of continuing demographic changes and the introduction of new public health measures. METHODS: All cases in which vitamin D deficiency was suspected as the primary cause of the clinical presentation were studied. RESULTS: Between 2002 and 2008, 160 cases of symptomatic vitamin D deficiency were identified with twice as many cases in 2008 (n, 42) as in the previous years. The median age of the cohort was 24 months (range 2 weeks-14 years).Three cases were recorded in children of European background, whereas the rest were in children of South Asian, Middle Eastern or sub-Saharan ethnic background. Presenting features included bowed legs in 64 (40%) and a fit in 19 (12%). In one infant, concerns were raised following a presentation with cardiac failure and hypocalcaemia. SUMMARY: Symptomatic vitamin D deficiency remains prevalent in the West of Scotland. There is a need for effective public health education, action and surveillance.


Subject(s)
Vitamin D Deficiency/ethnology , Adolescent , Age Distribution , Child , Child, Preschool , Female , Forecasting , Fractures, Bone/epidemiology , Fractures, Bone/etiology , Hospitals, Pediatric , Humans , Incidence , Infant , Infant, Newborn , Male , Radiography , Retrospective Studies , Rickets/diagnostic imaging , Rickets/epidemiology , Rickets/etiology , Scotland/epidemiology , Vitamin D Deficiency/complications
7.
Allergy Asthma Proc ; 22(6): 347-51, 2001.
Article in English | MEDLINE | ID: mdl-11775391

ABSTRACT

Theophylline was first isolated in 1888 and remains the most commonly used medication worldwide for the treatment of asthma. It decreases the need for asthma rescue medications by people who have asthma and is an effective steroid-sparing agent for patients who tolerate it. Recently, investigators have shown that theophylline decreases airway inflammation, accelerates eosinophil apoptosis, and decreases recruitment of lymphocytes and neutrophils to the lungs at low doses. It is classified as a phosphodiesterase (PDE) inhibitor, but its therapeutic mechanism of action remains undetermined. Theophylline should be reevaluated as a long-term medication for the treatment of asthma because of its ease of use, low cost, and recent evidence of its anti-inflammatory actions.


Subject(s)
Bronchodilator Agents/therapeutic use , Phosphodiesterase Inhibitors/therapeutic use , Theophylline/therapeutic use , Asthma/drug therapy , Bronchodilator Agents/pharmacokinetics , Bronchodilator Agents/standards , Dose-Response Relationship, Drug , Humans , Phosphodiesterase Inhibitors/pharmacokinetics , Phosphodiesterase Inhibitors/standards , Practice Guidelines as Topic , Theophylline/pharmacokinetics , Theophylline/standards , Treatment Outcome , United States , United States Food and Drug Administration
8.
Allergy Asthma Proc ; 22(6): 341-5, 2001.
Article in English | MEDLINE | ID: mdl-11775390

ABSTRACT

The importance of discovering and treating hidden factors that exacerbate asthma as specified in component 2 of the 1997 National Heart Lung and Blood Institute (NHLBI) expert panel report guidelines has been overshadowed by a disproportionate emphasis on component 3 (pharmacologic therapy). This has resulted in disease management models that consist of a two-step classification-treatment system in which little regard is given to the evaluation of underlying contributing factors. In addition to the identification of environmental allergens, an aggressive evaluation of other potential factors that may contribute to asthma is essential to optimal, efficient, and cost-effective asthma care. These factors include sinusitis, allergic rhinitis, and gastroesophageal reflux. Diagnostic testing for sinusitis and/or gastroesophageal reflux is warranted even in the absence of suggestive signs or symptoms for many patients with asthma classified in the moderate and severe ranges by NHLBI guidelines. A disease management algorithm for gastroesophageal reflux disease in the patient with asthma is proposed.


Subject(s)
Asthma/etiology , Air Pollutants/adverse effects , Alcohol Drinking , Allergens/adverse effects , Asthma/epidemiology , Asthma/therapy , Environmental Exposure/adverse effects , Gastroesophageal Reflux/complications , Gastroesophageal Reflux/diagnosis , Gastroesophageal Reflux/therapy , Heroin Dependence , Humans , Practice Guidelines as Topic , Prevalence , Rhinitis, Allergic, Perennial/complications , Rhinitis, Allergic, Perennial/diagnosis , Rhinitis, Allergic, Perennial/therapy , Risk Factors , Sinusitis/complications , Sinusitis/diagnosis , Sinusitis/therapy , Smoking/adverse effects
9.
Anticancer Res ; 20(5B): 3347-55, 2000.
Article in English | MEDLINE | ID: mdl-11131634

ABSTRACT

The deoxyadenosine-resistant mouse leukemia L1210 cell line (Y8) has previously been shown to have phenotypic differences that appear to be unrelated to the altered properties observed at the level of ribonucleotide reductase (RR). One of these changes is that the Y8 cells do not express p53. In response to DNA damaging agents, x-irradiation and doxorubicin, both the parental wild-type L1210 (WT) and Y8 cells undergo G2/M arrest, which is consistent with cells lacking wild-type p53 function. However, Y8 cells are much more sensitive to apoptosis induced by these agents than WT cells. Previous studies have also shown that expression of certain genes involved in cell cycle regulation is different between WT and Y8 cells. Recent evidence suggests that a serine/threonine kinase is involved in the divergent cellular responses of these cells. In the present study, the effects of roscovitine, a cyclin-dependent kinase inhibitor, were examined on the WT and Y8 cells. The WT cells blocked in G2/M, whereas Y8 cells became apoptotic. Apoptosis induced by roscovitine in the Y8 cells was mediated by a caspase-3-like activity. NF kappa B was activated to a much greater extent by roscovitine in the WT cells than in Y8 cells. The data also indicate that cyclin B1/cdc2 plays a role in the divergent p53-independent G2/M block and apoptotic responses of the WT and Y8 cells, respectively. Several key factors such as cathepsin B, caspase-1, release of cytochrome c into the cytosol, TNF-alpha signaling, FasL/Fas signaling, c-myc overexpression, and E2F-1 overexpression and induction were shown not to be involved in the apoptotic pathway(s) in the Y8 cells.


Subject(s)
Antineoplastic Agents/pharmacology , Apoptosis/drug effects , Caspases/metabolism , Deoxyadenosines/pharmacology , Leukemia L1210/pathology , Purines/pharmacology , Animals , Apoptosis/physiology , CDC2 Protein Kinase/metabolism , Caspase 3 , Caspase Inhibitors , Cathepsins/antagonists & inhibitors , Cell Cycle/drug effects , Cyclin B/metabolism , Cyclin B1 , Cyclin-Dependent Kinases/antagonists & inhibitors , Cysteine Proteinase Inhibitors/pharmacology , Cytochrome c Group/metabolism , Drug Resistance, Neoplasm , Enzyme Inhibitors/pharmacology , Leukemia L1210/drug therapy , Leukemia L1210/enzymology , Mice , NF-kappa B/metabolism , Oligopeptides/pharmacology , Proto-Oncogene Proteins c-myc/metabolism , Roscovitine
10.
Int J Oncol ; 17(4): 797-803, 2000 Oct.
Article in English | MEDLINE | ID: mdl-10995894

ABSTRACT

The deoxyadenosine-resistant mouse leukemia L1210 cell line (Y8) has previously been shown to be more sensitive to apoptosis induced by DNA damaging agents and by protein synthesis inhibitors than the parental wild-type L1210 (WT) cells. These responses occur independently of p53 as both cell lines lack wild-type p53 function. Recent evidence suggests that a serine/threonine kinase is involved in the divergent cellular responses of the WT and Y8 cells. In the present study, the effects of 7-hydroxystaurosporine (UCN-01), a relatively specific serine/threonine kinase inhibitor, were examined in the WT and Y8 cells. Both cell lines were equally sensitive to the growth inhibitory effects of UCN-01. However, the Y8 cells accumulated in G0/G1 and became apoptotic. Apoptosis induced by UCN-01 in the Y8 cells was mediated by a caspase-3-like activity which could be partially blocked by Ac-DEVD-CHO, a caspase-3 inhibitor. UCN-01 did not alter the phosphorylation status of cdc2 nor cyclin B1 and cdc2 protein levels in either cell line.


Subject(s)
Alkaloids/pharmacology , Apoptosis/drug effects , Deoxyadenosines/pharmacology , Enzyme Inhibitors/pharmacology , Leukemia L1210/prevention & control , Amino Acid Chloromethyl Ketones/pharmacology , Animals , CDC2 Protein Kinase/drug effects , CDC2 Protein Kinase/metabolism , Caspase 3 , Caspase Inhibitors , Caspases/drug effects , Caspases/metabolism , Cathepsins/antagonists & inhibitors , Cell Cycle/drug effects , Coumarins/pharmacology , Cyclin B/drug effects , Cyclin B/metabolism , Cyclin B1 , Cysteine Proteinase Inhibitors/pharmacology , Cytochrome c Group/drug effects , Cytochrome c Group/metabolism , Dose-Response Relationship, Drug , Drug Resistance, Neoplasm , Flow Cytometry , Leukemia L1210/pathology , Mice , Oligopeptides/pharmacology , Protein Kinase C/antagonists & inhibitors , Sensitivity and Specificity , Staurosporine/analogs & derivatives , Tumor Cells, Cultured
12.
J Chromatogr B Biomed Sci Appl ; 732(1): 81-9, 1999 Sep 10.
Article in English | MEDLINE | ID: mdl-10517225

ABSTRACT

Granulocyte colony-stimulating factor (G-CSF) is a glycoprotein which acts primarily to stimulate the proliferation, differentiation and activation of committed progenitor cells of the neutrophil-granulocyte lineage into functionally mature neutrophils. The traditional biological assays employed to detect G-CSF are a myeloid bone marrow colony assay, a factor-dependent cell line specific for G-CSF and commercially available immunoassays. However, these methods will not distinguish between glycosylated and non-glycosylated forms of the molecule. In this study high-performance capillary electrophoresis (HPCE) was used to analyse glycosylated and non-glycosylated recombinant human granulocyte colony-stimulating factor (r-met-hG-CSF). Glycosylated G-CSF preparations contained human serum albumin (HSA), added as a protein carrier. Glycosylated and non-glycosylated G-CSFs were prepared in 40 mM Na2HPO4 buffer, pH 2.5, containing hydroxypropylmethylcellulose (HPMC) or 50 mM Na2HPO4 buffer, pH 9.0. Glycosylated G-CSF could be separated into two distinct glycoform populations at the lower pH studied. Differences in migration time and peak shape between glycosylated and non-glycosylated G-CSF were demonstrated. HPCE analysis of G-CSF produced using a baculovirus expression vector system revealed a further distinct G-CSF glycoform and demonstrated the resolving power of the technique.


Subject(s)
Electrophoresis, Capillary/methods , Granulocyte Colony-Stimulating Factor/analysis , Glycoproteins/analysis , Glycosylation , Humans , Protein Isoforms/analysis , Recombinant Proteins/analysis
13.
Anticancer Res ; 19(2A): 1021-6, 1999.
Article in English | MEDLINE | ID: mdl-10368649

ABSTRACT

The deoxyadenosine-resistant mouse leukemia L1210 cell line (Y8) has previously been shown to have phenotypic differences that appear unrelated to the altered properties observed at the level of ribonucleotide reductase (RR). In response to various stress factors, the parental wild-type (WT) L1210 cell line undergoes cell cycle arrest; Y8 cells become apoptotic. These responses are p53-independent. Cell cycle regulation also appears different between the two cell lines, suggesting that Y8 cells are more apoptotic because of alterations in their cell cycle compared to WT cells. In order to study the relationships between cell cycle regulation and apoptosis, the effects of 2-aminopurine (2-AP), wortmannin, and PD98059, were studied on WT and Y8 cells. 2-AP induced G2/M block in both WT and Y8 cells with differences in G0/G1 and S phase contents between the two cell lines. Wortmannin induced G0/G1 block in Y8 cells, while exhibiting no effect on WT cells. PD98059 had no effect on the cell cycle of either WT or Y8 cells. In response to each inhibitor, Y8 cells underwent apoptosis to a much greater extent than the parental WT cell line. These data suggest that the specific pathways that converge on the cell cycle are altered and may be involved in the differences between a tumor cell to block in cell cycle or to undergo apoptosis.


Subject(s)
2-Aminopurine/pharmacology , Androstadienes/pharmacology , Deoxyadenosines/pharmacology , Flavonoids/pharmacology , Leukemia L1210/drug therapy , Animals , Apoptosis/drug effects , Drug Resistance, Neoplasm , G2 Phase/drug effects , Leukemia L1210/pathology , Mice , Mitosis/drug effects , Tumor Cells, Cultured , Wortmannin
14.
Exp Hematol ; 26(5): 435-9, 1998 May.
Article in English | MEDLINE | ID: mdl-9590661

ABSTRACT

Myelodysplastic syndrome (MDS) is a group of hematopoietic disorders characterized by peripheral cytopenias in the presence of normo- or hypercellular dysplastic marrow. It has been suggested that premature intramedullary apoptosis may contribute to this phenomenon. We used terminal dUTP nick-end labeling (TUNEL) of bone marrow biopsy specimens and cytocentrifuge preparations from patients with MDS and a variety of other hematopoietic disorders to determine whether there is increased intramedullary apoptosis in MDS and whether any such effect is specific to MDS. TUNEL labeling of bone marrow from 24 patients with MDS revealed significant positivity in 10 of 11 patients with refractory anemia (RA), five of seven with RA and excess of blasts (RAEB), all three patients with RAEB in transformation (RAEB-t), and all three patients with RA with ring sideroblasts (RARS). The percent of positive cells ranged from 5 to 50% but showed no apparent correlation with morphological subtype. In a series of 29 patients with acute leukemia, 17 showed significant positivity (13 of 13 with myeloid disease: three M1, seven M2, one M3, two M4; four of 16 patients with lymphoid disease: one Burkitt-type lymphoma, two null acute leukemia, and one common acute lymphoid leukemia). Intramedullary apoptosis was associated with myeloid or early committed progenitor cells and was highest in secondary acute myeloid leukemia (AML). Normal bone marrow samples from 12 individuals showed no evidence of apoptosis. Our results suggest that an increased level of intramedullary apoptosis is apparent in both patients with MDS and those with AML; those with secondary AML have the highest levels. The relative absence of such findings in lymphoid malignancy suggests that the apoptotic pathways are different in this lineage.


Subject(s)
Apoptosis/physiology , Bone Marrow Cells/cytology , Myeloproliferative Disorders/pathology , Biopsy , Centrifugation , Coloring Agents , Genetic Techniques , Humans , Leukemia, Myeloid, Acute/pathology , Myelodysplastic Syndromes/pathology , Precursor Cell Lymphoblastic Leukemia-Lymphoma/pathology
15.
Adv Enzyme Regul ; 37: 3-16, 1997.
Article in English | MEDLINE | ID: mdl-9381977

ABSTRACT

Mouse leukemia L1210 cells were generated for resistance to deoxyguanosine by two different methods. In one case the L1210 cells were subjected to gradual increases in deoxyguanosine (dGuo-R); in the second approach, the cells were subjected to deoxyguanosine at a concentration ten times the IC50 value and plated out on soft agar (D-92). The dGuo-R and D-92 cell lines had different phenotypic expressions. The dGuo-R cells showed a higher degree of resistance to dGuo than the D-92 cells. The levels of resistance to other cytotoxic drugs such as araC or 2-chloro-2'-deoxyadenosine did not necessarily correlate with the degree of resistance to dGuo. Deoxycytidine kinase activity was decreased in both of the cell lines, although there was a larger decrease in the dGuo-R cell line. The levels of kinase activities toward the other substrates were not all coordinately decreased in these cell lines. The degree of resistance of these cell lines to dGuo cannot be ascribed solely to an alteration at the deoxycytidine kinase site.


Subject(s)
Deoxyguanosine/pharmacology , Drug Resistance, Neoplasm , Leukemia L1210/pathology , Animals , Cell Division/drug effects , Cladribine/pharmacology , Cytarabine/pharmacology , Deoxycytidine/pharmacology , Deoxycytidine Kinase/metabolism , Kinetics , Leukemia L1210/enzymology , Mice , Phosphotransferases (Alcohol Group Acceptor)/metabolism , Tumor Cells, Cultured
16.
J Immunol ; 149(6): 2123-9, 1992 Sep 15.
Article in English | MEDLINE | ID: mdl-1517575

ABSTRACT

Mouse bone marrow-derived mast cells (BMMC) obtained by culturing progenitor cells with rIL-3 express mouse mast cell protease (MMCP)-5 mRNA but not MMCP-1 mRNA or MMCP-4 mRNA. In terms of mast cell differentiation, these transcripts encode one early-expressed and two late-expressed chymases, respectively. cDNA and cRNA probes were used in RNase protection assays and RNA blot analyses to study the expression of these three homologous protease genes in cultured mast cells and in helminth-infected mice. Intestinal tissue from Trichinella spiralis-infected mice, containing high numbers of mucosal mast cells, had abundant amounts of MMCP-1 mRNA but only minimal amounts of the serosal mast cell transcript that encodes MMCP-4. Exposure of mouse BMMC to rIL-10-induced transcription of the MMCP-1 gene but not the MMCP-4 gene, and a cDNA encoding MMCP-1 was obtained from these rIL-10-treated cells. The expression of MMCP-1 mRNA in BMMC depended on the continuous exposure of these cells to rIL-10, and the level of MMCP-1 mRNA (but not MMCP-5 mRNA) was substantially higher in BMMC maintained in rIL-4 and rIL-10 than in rIL-3 and rIL-10 or in rIL-3, rIL-4, and rIL-10. Thus, whereas rIL-3 elicits transcription of early expressed genes in cultured mast cells, it suppresses the transcription of late-expressed genes. These in vitro and in vivo transcription studies also indicate that rIL-10 preferentially induces differentiation of mouse progenitor cells in a mucosal mast cell-specific lineage, and that expression of granule serine protease genes is regulated in a subclass-specific manner in mouse mucosal mast cells and serosal mast cells.


Subject(s)
Interleukin-10/pharmacology , Mast Cells/enzymology , Serine Endopeptidases/genetics , Trichinellosis/immunology , Amino Acid Sequence , Animals , Base Sequence , Chymases , DNA/genetics , Gene Expression/drug effects , Genes , Intestines/enzymology , Mice , Molecular Sequence Data , RNA, Messenger/genetics , Trichinella/immunology
17.
Arthritis Rheum ; 35(3): 325-35, 1992 Mar.
Article in English | MEDLINE | ID: mdl-1536671

ABSTRACT

OBJECTIVE: To determine the consequences of mast cell (MC)-chondrocyte interactions. METHODS: Cocultured cells were analyzed histochemically, morphologically, biochemically, and functionally. RESULTS: Cocultured MC adhered to the chondrocytes and remained viable. Chondrocytes cocultured with nonactivated MC produced more proteoglycans than did chondrocytes cultured alone, and these proteoglycans possessed an intact hyaluronic acid-binding region. In contrast, most of the proteoglycans produced by chondrocytes cocultured with activated MC were degraded. CONCLUSION: These studies indicate that a complex interaction occurs in which the nonactivated MC stimulates biosynthesis and the activated MC degrades cartilage proteoglycans.


Subject(s)
Cartilage, Articular/cytology , Mast Cells/cytology , Proteoglycans/metabolism , Animals , Cartilage, Articular/metabolism , Cell Survival , Cells, Cultured/ultrastructure , Chondrosarcoma/pathology , Rats , Rats, Inbred Strains , Sulfur Radioisotopes , Time Factors , p-Methoxy-N-methylphenethylamine/pharmacology
18.
J Biol Chem ; 266(30): 20316-22, 1991 Oct 25.
Article in English | MEDLINE | ID: mdl-1939089

ABSTRACT

cDNAs were isolated that encode mouse mast cell protease-5 (MMCP-5), an approximately 30,000 Mr serine protease stored in the secretory granules of serosal mast cells (SMC) and Kirsten sarcoma virus-immortalized mast cells. Based on the deduced amino acid sequences of these cDNAs, MMCP-5 is synthesized as a 247-amino acid preproenzyme composed of a novel 19-residue hydrophobic signal peptide, a Gly-Glu activation peptide not present in other mast cell chymases, and a 226-amino acid protein that represents the mature enzyme. MMCP-5 possesses a unique Asn residue in the substrate binding cleft at residue 176 and is highly basically charged. The MMCP-5 gene was isolated, sequenced, and found to belong to a distinct subset of chymase genes. Allelic variations of the MMCP-5 gene were also detected. MMCP-5 is expressed in bone marrow-derived mast cells (BMMC), Kirsten sarcoma virus-immortalized mast cells, and SMC, but not in gastrointestinal mucosal mast cells of helminth-infected mice. The abundant levels of MMCP-5 mRNA in immature BMMC indicate that this chymase is expressed relatively early during the differentiation of mast cells. MMCP-5 is the first chymase to be molecularly cloned from progenitor mast cells and is also the first chymase shown to be expressed preferentially in the SMC subclass.


Subject(s)
Cytoplasmic Granules/enzymology , Mast Cells/enzymology , Serine Endopeptidases/genetics , Amino Acid Sequence , Animals , Base Sequence , Blotting, Southern , Chymases , Cloning, Molecular , DNA/genetics , Gene Expression , Mice , Molecular Sequence Data , Serine Endopeptidases/metabolism , Substrate Specificity , TATA Box , Transcription, Genetic
19.
Food Addit Contam ; 6 Suppl 1: S33-9, 1989.
Article in English | MEDLINE | ID: mdl-2599154

ABSTRACT

Metabolic and kinetic data on pesticides are now becoming an important part of the toxicological dossier required for product registration. In this paper the approach by one agrochemical company to generating such data is discussed. Metabolic data for the acaricide clofentezine are presented to illustrate why such data should be regarded as not only an important registration requirement, but also as integral to understanding the toxicological profile of pesticides.


Subject(s)
Pesticides/toxicity , Animals , Cattle , Chlorobenzenes/toxicity , Dogs , Enzyme Induction/drug effects , Female , Humans , Male , Mice , Pesticides/metabolism , Pesticides/pharmacokinetics , Rabbits , Rats , Tissue Distribution
20.
Arch Biochem Biophys ; 262(1): 118-29, 1988 Apr.
Article in English | MEDLINE | ID: mdl-3355162

ABSTRACT

Titin and nebulin are two major protein components of a cytoskeletal matrix that coexists with thick and thin filaments within the sarcomere of a wide range of striated muscles. Purified titin and nebulin from mouse diaphragm muscle are similar in size, in relative abundance, and in amino acid composition to analogous proteins from other mammals or avians. Phosphate analysis of these nucleic-acid-free proteins indicated that both proteins contain substantial amounts of protein-bound phosphate: about 12 mol of phosphate per mole of titin subunit and 11 mol of phosphate per mole of nebulin subunit. Incubation of intact, excised mouse diaphragm with radioactive inorganic phosphate resulted in significant incorporation of radiophosphate into titin and nebulin. The identification of titin and nebulin phosphorylation was facilitated by a simple salt fractionation and nuclease digestion procedure that effectively separated titin and nebulin from radiolabeled nucleic acids. Such in vivo phosphorylation studies indicated that approximately 2 mol of phosphate per titin subunit and 5 to 7 mol of phosphate per nebulin subunit were incorporated within 5 h of incubation. The incorporation nearly doubled when the beta-adrenergic agonist, isoproterenol, or a phosphodiesterase inhibitor, theophylline, was present in the medium. For both proteins, phosphorylation occurred mainly on serine residues. Nebulin also appears to possess a smaller number of threonine sites. Taken together, our data indicate that a small proportion (20 to 40%) of the steady-state titin phosphates are rapidly turning over. In contrast, most of the nebulin phosphates (50 to 100%) are readily exchanged. The modulation of turnover by external stimuli that increase cytosolic cAMP raises the possibility that at least a portion of the multiple phosphorylation sites of titin and nebulin may be involved in the functional regulation of the sarcomere matrix.


Subject(s)
Muscle Proteins/metabolism , Muscles/ultrastructure , Myofibrils/ultrastructure , Protein Kinases , Sarcomeres/ultrastructure , Amino Acids/analysis , Animals , Connectin , Electrophoresis, Polyacrylamide Gel , Isoproterenol/pharmacology , Male , Mice , Muscles/metabolism , Phosphorylation
SELECTION OF CITATIONS
SEARCH DETAIL
...